Home › Funds › Medicxi Ventures Management (Jersey) Ltd › NAMS

Medicxi Ventures Management (Jersey) Ltd position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

Medicxi Ventures Management (Jersey) Ltd reported holding 2,182,339 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$53.1M, representing 41.90% of its reported portfolio and ranking #2 among its reported holdings. Medicxi Ventures Management (Jersey) Ltd has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.18M sh
Reported value held$53.07M
Portfolio Weight41.90%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Medicxi Ventures Management (Jersey) Ltd's NAMS position evolved

Medicxi Ventures Management (Jersey) Ltd first disclosed a stake in NAMS in Q3 2023 at 2,869,565 shares (US$26.5M). The position peaked in Q4 2025 at 2,869,565 shares, worth US$100.7M. Across 13 filings, Medicxi Ventures Management (Jersey) Ltd increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 2,182,339 shares valued at US$53.1M — a reduction of -26,300 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.87M $26.54M New
Q4 2023 2.87M $32.05M Hold
Q1 2024 2.87M $67.87M Hold
Q2 2024 2.87M $55.12M Hold
Q3 2024 2.87M $47.63M Hold
Q4 2024 2.87M $73.75M Hold
Q1 2025 2.87M $58.74M Hold
Q2 2025 2.87M $51.97M Hold
Q3 2025 2.87M $81.61M Hold
Q4 2025 2.87M $100.66M Hold
Q1 2026 2.67M $85.60M Reduce
Q2 2026 2.21M $74.85M Reduce
Q3 2026 2.18M $53.07M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 41 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Medicxi Ventures Management (Jersey) Ltd held NAMS?

Medicxi Ventures Management (Jersey) Ltd has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Medicxi Ventures Management (Jersey) Ltd's current position in NAMS?

As of Q3 2026, Medicxi Ventures Management (Jersey) Ltd holds 2.18M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $53.07M, representing 41.90% of its reported portfolio and ranking #2.

Has Medicxi Ventures Management (Jersey) Ltd been buying or selling NAMS?

In the latest 13F filing (Q3 2026), Medicxi Ventures Management (Jersey) Ltd reduced its position in NAMS. The position peaked in Q4 2025 at 2.87M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.